The use of Platelet Additive Solution is a major step to improve transfusion safety thanks to a significant reduction of patient adverse reactions and ABO incompatibility.
Macopharma develops and manufactures solutions to improve the quality and the safety of platelets, allowing better patient outcome.
The recommended ratio is 70% SSP+ 30% Plasma (possible ratio up to 80% SSP+ 20% Plasma).
Since 2004, more than 8 millions of Platelet concentrates have been stored in SSP+, across more than 40 countries (Data from 2020).
IN VITRO QUALITY DATA AND CLINICAL EXPERIENCE
• Reports of haemovigilance from several countries demonstrate a significant reduction in the rate of allergic events wih platelets suspended in PAS compared to platelets suspended in plasma.
• Platelet concentrates from Buffy-Coat in SSP+ additive solution show superior in vitro parameters when compared with those stored in plasma. (Storage of platelet concentrates -Present and future, P. Van der Meer.)
• Novel PAS containing glucose, calcium and bicarbonate does not seem to be associated with improved in vitro results as compared to SSP+ when PLTs are stored with 35% plasma inclusion. (Platelet storage media, H. Gulliksson.)
• HSR, regarded as one of the best single in vitro parameters to predict post-transfusion efficacy, is higher after 7-day storage in SSP+ as compared to Intersol. (in vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution, B. Diedrich et al.)
• SSP+ is effective for both preserving the in vitro properties of PLTs and preventing accelerated glycolysis. (Parallel comparison of apheresis collected platelet concentrates stored in four different additive solutions, M. Nogawa et al.)
• Storage of PLTs in SSP+ improved the quality of PCs in terms of better maintained PLT count, lower glucose metabolism, lower spontaneous activation, and improved response to a PLT agonist compared to PLTs in T-Sol. (in vitro properties of platelets stored in three different additive solutions, N. Tynngard et al.)
This information is for exclusive use of healthcare professionals.
The products are not available in every country, please contact your sales representative.
MACOPHARMA • Rue Lorthiois 59240 Mouvaux France • Tel : + 33 (0) 3 20 11 84 00 • Fax : +33 (0) 3 20 11 84 03
Société par actions simplifiée au Capital de 493.115 € RCS Lille Metropole 391 600 905 • Code APE 4641 Z • TVA FR 313 916 009 05
